Eurobio Onkologie

EndoPredict®: Test Procedure

Intended Use1

The EndoPredict® QS Kit is an in vitro diagnostic product for patients with estrogen-receptor-positive, HER2-negative primary breast cancer to determine the risk of distant recurrence and to estimate the adjuvant chemotherapy benefit. 

For the intended purpose, the EndoPredict® QS Kit may only be applied to RNA samples extracted from formalin-fixed, paraffin-embedded breast cancer tissue.

The EndoPredict QS Kit is designed for use by experts trained in the assay techniques required for performance of the test and in the application of the system. The results of the EndoPredict test may be used only in the proper context, together with other established methods and clinical/pathological factors for the prognosis and stratification of patients with breast cancer.

For the intended purpose, the EndoPredict® QS UNO and DUO Kits may only be applied to RNA samples extracted from formalin-fixed, paraffin-embedded breast cancer tissue using any of the following RNA extraction kits or reagents:

  • RNeasy® DSP FFPE Kit (QIAGEN®)
  • RNeasy® FFPE Kit (QIAGEN®) with Deparaffinization solution (QIAGEN®)
  • miRNeasy FFPE Kit (QIAGEN®) with Deparaffinization solution (QIAGEN®)
  • Maxwell® CSC RNA FFPE Kit (Promega)
  • Maxwell® RSC RNA FFPE Kit (Promega)

Moreover, the EndoPredict QS UNO and DUO Kits may only be used in combination with the EndoPredict Report Generator and together with the
following Real-Time PCR Instrument:

  • QuantStudio™ 5 Dx Real-Time PCR System (Thermo Fisher Scientific) and the corresponding EndoPredict template files

Performance characteristics of the EndoPredict test have only been established for women with estrogen-receptor positive, HER2-negative breast cancer treated with either adjuvant endocrine therapy alone or adjuvant endocrine therapy plus chemotherapy after resection. They are not established for patients treated prior to resection with systemic therapy (e.g. chemotherapy or endocrine therapy) or radiation therapy.

How to perform the EndoPredict® Test

1. Sampling1

EndoPredict is performed on FFPE tumor tissue from treatment-naïve biopsy or surgical specimens. To ensure high-quality results, the following criteria should be met:​

2. RNA Isolation1

RNA extraction can be performed manually or automatically, with a turnaround time of 3 hours per 12 samples. The following RNA extraction kits and reagents are validated for use:

3. Analysis1

EndoPredict is validated for use with the QuantStudio™ 5 Dx Real-Time PCR instrument and QuantStudio™ 5 Dx IVD software from Thermo Fisher Scientific®.​

4. Result1

The result report (including quality control) is generated using a web-based software, the EndoPrededict® Report Generator (EPRG).
Not yet a partner lab? You can try it out yourself by generating a sample report using the EndoPredict® Report Generator and the demo data files available in the download section of the EPRG.​

So bestellen Sie ein EndoPredict® Test

Der prognostische und prädiktive Brustkrebstest EndoPredict wird in zertifizierten lokalen Labors durchgeführt und liefert innerhalb weniger Tage zuverlässige Ergebnisse.

Ärzte können EndoPredict bequem über ein breites Netz von teilnehmenden Labors bestellen. Über den unten stehenden Link können Sie ein lokales Labor finden und Ihre Bestellung aufgeben. Haben Sie Fragen? Wenden Sie sich jederzeit an uns - wir sind für Sie da.

Get the EndoPredict® Test in Your Lab​

EndoPredict is available as a CE-marked IVD kit that can be run in local molecular pathology laboratories after a comprehensive onsite training, provided by Eurobio Scientific.​

Interested in offering EndoPredict in your lab? Use the contact form below – we’ll evaluate the requirements together.

  1. EndoPredict® QS for QuantStudio™ 5 Dx Instruction Manual Version EN/03 2025
de_DE
Nach oben scrollen